.Attributes Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in boosted progression-free and total survival, leading to FDA approval and a brand new therapy possibility for individuals.